$FENC
FENNEC PHARMACEUTICALS INC.

2015 Q3 Form 10-Q Financial Statement

#000114420415064637 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $250.0K $530.0K $860.0K
YoY Change -52.83% 89.29% 132.43%
% of Gross Profit
Research & Development $88.00K $88.00K $72.00K
YoY Change 0.0% -139.29% -87.0%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $88.00K $88.00K $72.00K
YoY Change 0.0% 72.55% -92.23%
Operating Profit -$338.0K -$619.0K -$930.0K
YoY Change -45.4% 1113.73% 0.32%
Interest Expense $220.0K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $215.0K $999.0K $180.0K
YoY Change -78.48% -158.25% -97.61%
Pretax Income -$120.0K $380.0K -$750.0K
YoY Change -131.58% -121.47% -111.35%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$123.0K $380.0K -$750.0K
YoY Change -132.37% -121.52% -111.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 $0.04 -$0.08
Diluted Earnings Per Share -$0.01 $0.03 -$0.08
COMMON SHARES
Basic Shares Outstanding 10.93M shares 9.861M shares 9.846M shares
Diluted Shares Outstanding 10.93M shares 11.15M shares 9.846M shares

Balance Sheet

Concept 2015 Q3 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.370M $590.0K $1.020M
YoY Change 132.2% 9.26% 0.99%
Cash & Equivalents $1.366M $593.0K $1.015M
Short-Term Investments
Other Short-Term Assets $80.00K $13.00K $40.00K
YoY Change 515.38% 1200.0% 1233.33%
Inventory
Prepaid Expenses $67.00K
Receivables
Other Receivables
Total Short-Term Assets $1.450M $670.0K $1.050M
YoY Change 116.42% 4.69% 1.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $3.000K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.450M $670.0K $1.050M
Total Long-Term Assets $0.00 $3.000K $0.00
Total Assets $1.450M $673.0K $1.050M
YoY Change 115.45% 5.16% 1.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $250.0K $364.0K $340.0K
YoY Change -31.32% 15.56% -52.51%
Accrued Expenses $90.00K $38.00K $40.00K
YoY Change 136.84% -41.54% -38.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $430.0K $3.901M $5.710M
YoY Change -88.98% -18.22% 65.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $430.0K $3.901M $5.710M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $430.0K $3.901M $5.710M
YoY Change -88.98% -18.17% 65.08%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $107.8M
YoY Change 3.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.019M -$3.228M -$4.658M
YoY Change
Total Liabilities & Shareholders Equity $1.450M $673.0K $1.050M
YoY Change 115.45% 5.16% 1.94%

Cashflow Statement

Concept 2015 Q3 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income -$123.0K $380.0K -$750.0K
YoY Change -132.37% -121.52% -111.35%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$509.0K -$443.0K -$410.0K
YoY Change 14.9% -5.54% -53.88%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.00K $87.00K
YoY Change
Debt Paid & Issued, Net $0.00 $0.00
YoY Change
Cash From Financing Activities $21.00K $21.00K $87.00K
YoY Change 0.0%
NET CHANGE
Cash From Operating Activities -$509.0K -$443.0K -$410.0K
Cash From Investing Activities $0.00 $0.00 $0.00
Cash From Financing Activities $21.00K $21.00K $87.00K
Net Change In Cash -$488.0K -$422.0K -$323.0K
YoY Change 15.64% -10.02% -63.67%
FREE CASH FLOW
Cash From Operating Activities -$509.0K -$443.0K -$410.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$443.0K -$410.0K
YoY Change -5.54% -53.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2014Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
122000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
999000 USD
CY2015Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1000 USD
CY2014Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
215000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-123000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
380000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10791000 shares
CY2015Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-149000 USD
CY2014Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
30000 USD
CY2015Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
37000 USD
CY2014Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2000 USD
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
9000 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
67000 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-509000 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-443000 USD
CY2015Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
69000 USD
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10929000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861000 shares
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10929000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11154000 shares
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1154000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1894000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1339000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2086000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1226000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1855000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1220000 USD
us-gaap Net Income Loss
NetIncomeLoss
-119000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3564000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10791000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9861000 shares
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192000 USD
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 USD
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
28000 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2015Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2014Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2015Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-488000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-422000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1854000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1015000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
593000 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21000 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21000 USD
CY2015Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000 USD
CY2014Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000 USD
CY2014Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
42000 USD
CY2015Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2000 USD
CY2014Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
251000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
28000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
539000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1438000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1231000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-941000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1070000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1663000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
497000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
497000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
161000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
35000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-14000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-56000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
152000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-46000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-94000 USD
CY2015Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1366000 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2307000 USD
CY2015Q3 us-gaap Cash
Cash
49000 CAD
CY2015Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
93000 USD
CY2015Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
694000 USD
CY2014Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1319000 USD
CY2014Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
3499000 USD
CY2015Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
309000 USD
CY2015Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2594000 shares
CY2010Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6666000 shares
CY2010Q2 fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
CY2015Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
9000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1366000 USD
CY2015Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
93000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3000 USD
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1293000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10939000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10939000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10593000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10593000 shares
CY2015Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2014Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
379000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
379000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include valuation of derivative warrant liability and the value of stock based compensation.&#160;Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the opinion of management, these unaudited interim condensed consolidated financial statements include all normal and recurring adjustments considered necessary for the fair presentation of the Company&#8217;s financial position at September 30, 2015 and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 4. There were significant changes in their valuation during the quarter ended, and for the nine-month period ended September 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3 us-gaap Cash
Cash
13000 USD
CY2014Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
189000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
790000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0190 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.39 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.39 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2014Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Board of Directors approved a 1-for-18 and a 1-for-3 reverse stock split
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
combined 1-for-54 reverse stock split
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.25 pure
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000 USD
CY2015Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000 USD
CY2015Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 USD
CY2014 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
21000 USD
CY2015Q2 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
449000 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1570000 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2182000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
1845000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
177000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-173000 USD
CY2014 fencf Exchange Of Warrants
ExchangeOfWarrants
840000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-4957000 USD

Files In Submission

Name View Source Status
0001144204-15-064637-index-headers.html Edgar Link pending
0001144204-15-064637-index.html Edgar Link pending
0001144204-15-064637.txt Edgar Link pending
0001144204-15-064637-xbrl.zip Edgar Link pending
fencf-20150930.xml Edgar Link completed
fencf-20150930.xsd Edgar Link pending
fencf-20150930_cal.xml Edgar Link unprocessable
fencf-20150930_def.xml Edgar Link unprocessable
fencf-20150930_lab.xml Edgar Link unprocessable
fencf-20150930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tex10-40logo.jpg Edgar Link pending
tex99-1logo.jpg Edgar Link pending
v423959_10q.htm Edgar Link pending
v423959_ex10-40.htm Edgar Link pending
v423959_ex31-1.htm Edgar Link pending
v423959_ex31-2.htm Edgar Link pending
v423959_ex32-1.htm Edgar Link pending
v423959_ex99-1.htm Edgar Link pending